9,013,571 Shares in CVS Health Corporation $CVS Purchased by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon acquired 9.01 million CVS Health shares worth approximately $932.5 million, representing about 0.71% of the company. Institutional investors collectively own 80.66% of CVS.
• Analyst sentiment remains positive, with 22 Buy ratings and two Holds, producing a consensus “Moderate Buy” rating and an average price target of $107.17.
• CVS exceeded quarterly expectations, reporting $2.58 in EPS and $106.1 billion in revenue, while maintaining FY 2026 EPS guidance of $7.90–$8.10 and a $0.665 quarterly dividend.

Bank of New York Mellon Corp purchased a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,013,571 shares of the pharmacy operator's stock, valued at approximately $932,454,000. Bank of New York Mellon Corp owned about 0.71% of CVS Health as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator's stock worth $9,579,508,000 after buying an additional 1,824,424 shares in the last quarter. State Street Corp raised its holdings in CVS Health by 2.1% in the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator's stock valued at $4,776,182,000 after acquiring an additional 1,245,457 shares in the last quarter. Capital International Investors raised its holdings in CVS Health by 3.4% in the fourth quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator's stock valued at $2,189,793,000 after acquiring an additional 900,153 shares in the last quarter. Norges Bank bought a new position in CVS Health during the 4th quarter valued at $1,666,265,000. Finally, Morgan Stanley grew its holdings in CVS Health by 6.3% during the 4th quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator's stock worth $1,616,863,000 after acquiring an additional 1,211,631 shares in the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CVS. Morgan Stanley upped their target price on shares of CVS Health from $106.00 to $111.00 and gave the company an "overweight" rating in a research note on Thursday, June 4th. JPMorgan Chase & Co. lifted their price target on CVS Health from $111.00 to $118.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. HSBC reissued a "hold" rating and issued a $103.00 price objective on shares of CVS Health in a report on Monday, July 6th. Argus increased their target price on CVS Health from $104.00 to $114.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Bank of America lifted their target price on CVS Health from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Monday, June 22nd. Twenty-two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $107.17.

CVS Health Trading Up 0.2%

CVS Health stock opened at $93.83 on Friday. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68. The firm's 50-day moving average is $102.19 and its 200-day moving average is $88.83. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The company has a market cap of $120.01 billion, a P/E ratio of 24.82, a PEG ratio of 0.89 and a beta of 0.61.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.87 by $0.71. The business had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. CVS Health's dividend payout ratio is 70.37%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source